IDEXX (IDXX) Business Faces Macroeconomic Woes, FX Headwinds

IDEXX Laboratories, Inc. (IDXX) has been facing uncertain macroeconomic conditions. Currency headwinds continue to dent profit. The stock carries a Zacks Rank #4 (Sell) currently. During the first quarter of 2024, foreign exchange had a limited impact on the gross margin, operating profit and earnings. IDEXX's updated 2024 revenue forecast includes a $35 million impact, equivalent to about a 1% decrease, due to the recent appreciation of the U.S. dollar. Key Picks Estimates for Medpace's 2024 earnings per s ...